Working with its French partner, Sylvan Bio, Gee Lawson highlighted the, “pharmaceutical grade facility from guaranteed Non-GMO European Organic rice”.
“Most red yeast rice comes to the market from China. Since both the inoculum and production facilities of our red yeast rice are located in Europe, Gee Lawson is able to confirm the total traceability and conditions of manufacture,” the company said.
The organic product will be available from September this year.
“This is the first time material has been manufactured in the UK and gives a distinct advantage to users against the traditional methods from the Far East,” Gee Lawson continued.
“With the [EU nutrition and health claims regulation (NHCR)] now in place the partnership believe it is an ideal time for both food manufacturers and supplement brands to offer the consumer quality ingredients to meet health claims.”
The company said it was working on further exploiting the positive health claim for red yeast rice that became EU law this year.
The opinion that was the basis for that claim can be found here.
It stated, “that a cause and effect relationship has been established between the consumption of monacolin K from red yeast rice and maintenance of normal blood LDL- cholesterol concentrations.”
“The Panel considers that in order to obtain the claimed effect, 10 mg of monacolin K from fermented red yeast rice preparations should be consumed daily.”